Atrium Therapeutics, Inc Common Stock

Yahoo Finance • 9 days ago

Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novartis (SWX:NOVN) issues US$11b in US dollar bonds to fund its planned US$12b acquisition of Avidity Biosciences. The bon... Full story

Yahoo Finance • 11 days ago

Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal

This article first appeared on GuruFocus. Novartis (NYSE:NVS) has raised $11 billion in the US dollar bond market to support its $12 billion acquisition of Avidity Biosciences, underscoring how large pharmaceutical companies are continuin... Full story

Yahoo Finance • 12 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 29 days ago

Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger

Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 23, Avidity Biosciences Inc. (NASDAQ:RNA) adjourned its spec... Full story

Yahoo Finance • 4 months ago

Novartis Drops $1.7 Billion on AI Allergy Breakthrough

This article first appeared on GuruFocus. Novartis (NYSE:NVS) is doubling down on AI-driven drug discovery with a deal that could be worth $1.7 billion, signaling rising conviction that data-intensive platforms may reshape how immunology... Full story

Yahoo Finance • 4 months ago

Dow Inc. (DOW): A Bull Case Theory

We came across a bullish thesis on Dow Inc. on Quipus Capital’s Substack. In this article, we will summarize the bulls’ thesis on DOW. Dow Inc.'s share was trading at $23.86 as of December 2nd. DOW’s trailing and forward P/E were 32.65 and... Full story

Yahoo Finance • 4 months ago

Avidity Biosciences, Inc. (RNA): A Bull Case Theory

We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by  AnotherBio. In this article, we will summarize the bulls’ thesis on RNA. Avidity Biosciences, Inc.'s share was trading at $71.54 as of December 2... Full story

Yahoo Finance • 4 months ago

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

Key Points Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no shares of MBX at the end of t... Full story

Yahoo Finance • 4 months ago

Guru Fundamental Report for RNA

Below is Validea's guru fundamental report for AVIDITY BIOSCIENCES INC (RNA). Of the 22 guru strategies we follow, RNA rates highest using our Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy l... Full story

Yahoo Finance • 4 months ago

Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 4 months ago

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its M... Full story

Yahoo Finance • 5 months ago

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company ("SpinCo") Clear path forward aligned... Full story

Yahoo Finance • 5 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE – WTRG), Cadence Bank (NYSE – CADE), Avidity Biosciences, Inc. (Nasdaq – RNA), Plymouth Industrial REIT, Inc. (NYSE – PLYM)

BALA CYNWYD, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 5 months ago

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger

We recently published 10 Stocks With Easy 20-40% Gains. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the last week's best-performing stocks. Avidity Biosciences climbed by 42.1 percent week-on-week, as investors gobbled up shares afte... Full story

Yahoo Finance • 5 months ago

RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidity sharehold... Full story

Yahoo Finance • 5 months ago

Novartis Profit Rises on Cancer Drug Momentum

This article first appeared on GuruFocus. Novartis (NYSE:NVS) had a solid quarter, with strong sales of its cancer drugs giving profits a nice lift. The Swiss pharma giant said core operating profit rose 6% year over year to $5.5 billion... Full story

Yahoo Finance • 5 months ago

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Argus upgraded Warner Bros. Discovery... Full story

Yahoo Finance • 5 months ago

Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger

We recently published 10 Big Names Crushing Wall Street. Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the top-performing stocks on Monday. Dyne Therapeutics soared by 41.18 percent on Monday to close at $24.17 apiece following a comment... Full story

Yahoo Finance • 5 months ago

Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis

We recently published 10 Big Names Crushing Wall Street. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the top-performing stocks on Monday. Shares of Avidity rallied to a new all-time high on Monday, as investors gobbled up shares foll... Full story

Yahoo Finance • 5 months ago

Novartis Q3 profit swells as oncology drugs drive growth

[Novartis] TBE/iStock Editorial via Getty Images Novartis (NYSE:NVS [https://seekingalpha.com/symbol/NVS]) reported a solid profit increase last quarter, driven by strong demand for its new cancer drugs. Core operating profit rose 6% Y/Y... Full story